WaveMan
WaveMan · Company
VIR · Vir Biotechnology, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

VIR Vir Biotechnology (VIR) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001706431
Quote by TradingView
Form 144 · 5
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
125
13F, latest reported quarter

What the filings say about VIR

Insiders, 180 days
-$254.9K net sold
3 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$1.2M
5 notices

Vir Biotechnology insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Vir Biotechnology, Inc. insiders sold a net $254.9K of stock across 337 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Napolitano Janet
Director
SELL
2026-06-02 SECtraded 2026-06-01
3,200
$30.2K
+31.9%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Jun 2, 2025.
  • The trade is 15.1% of the 21,216 shares held after it.
  • 1 other insider sold within 30 days.
  • 125 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Napolitano Janet sold about $30.2K of VIR on Jun 1, 2026; 1 other insider sold within 30 days and 125 funds added in the latest 13F quarter.
Sabatini Brent
SVP, Chief Accounting Officer
SELL
2026-06-02 SECtraded 2026-06-01
379
$3.6K
+31.9%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Mar 23, 2026.
  • The trade is 0.6% of the 61,902 shares held after it.
  • 1 other insider sold within 30 days.
  • 125 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Chief Accounting Officer Sabatini Brent sold about $3.6K of VIR on Jun 1, 2026; 1 other insider sold within 30 days and 125 funds added in the latest 13F quarter.
SATO VICKI L
Director
SELL
2026-05-04 SECtraded 2026-05-01
22,000
$221.1K
+15.6%
Context
  • 47 earlier Form 4 trades (code P or S) here by this insider (47 sales), the last on Apr 1, 2026.
  • The trade is 2.0% of the 1,078,391 shares held after it.
  • 1 other insider sold within 30 days.
  • 125 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director SATO VICKI L sold about $221.1K of VIR on May 1, 2026; 1 other insider sold within 30 days and 125 funds added in the latest 13F quarter.
De Backer Marianne
President and CEO
SELL
2026-04-07 SECtraded 2026-04-06
72,559
$664.6K
+21.5%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Feb 24, 2026.
  • The trade is 7.7% of the 948,145 shares held after it.
  • 2 other insiders sold within 30 days.
  • 125 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO De Backer Marianne sold about $664.6K of VIR on Apr 6, 2026; 2 other insiders sold within 30 days and 125 funds added in the latest 13F quarter.
SATO VICKI L
Director
SELL
2026-04-02 SECtraded 2026-04-01
22,000
$199.5K
+27.7%
Context
  • 46 earlier Form 4 trades (code P or S) here by this insider (46 sales), the last on Mar 2, 2026.
  • The trade is 2.0% of the 1,100,391 shares held after it.
  • 2 other insiders sold within 30 days.
  • 125 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director SATO VICKI L sold about $199.5K of VIR on Apr 1, 2026; 2 other insiders sold within 30 days and 125 funds added in the latest 13F quarter.
337 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 332 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$254.9K over 180 days
more than 50% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
125 funds bought in last quarter
more than 77% of Pharma & Biotech
Revenue
-7.6% year over year
below 64% of Pharma & Biotech
Margin
-638.9% net margin
below 80% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
11.5% of the float short (float per yahoo 2026-10-26) · 7.0 days to cover · settled 2026-09-30
more than 67% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch VIR

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+100.2%12M
-11%+27%+65%+104%2025-102025-122026-022026-042026-062026-082026-10 2025-11-25 · SVF Endurance (Cayman) Ltd sold $1.5M2025-11-24 · SVF Endurance (Cayman) Ltd sold $1.4M2025-12-01 · SVF Endurance (Cayman) Ltd sold $1.1M2025-10-23 · SB INVESTMENT ADVISERS (UK) LTD sold $924.8K2025-11-26 · SOFTBANK VISION FUND (AIV M1) L.P. sold $817.5K2026-04-06 · De Backer Marianne sold $664.6K2026-02-24 · SATO VICKI L sold $411.2K2025-10-27 · SB INVESTMENT ADVISERS (UK) LTD sold $401.7K2025-11-28 · SOFTBANK VISION FUND (AIV M1) L.P. sold $396.0K2025-10-24 · SB INVESTMENT ADVISERS (UK) LTD sold $278.3K2026-05-01 · SATO VICKI L sold $221.1K2026-03-02 · SATO VICKI L sold $207.1K2026-04-01 · SATO VICKI L sold $199.5K2026-02-02 · SATO VICKI L sold $169.6K2025-10-28 · SVF Endurance (Cayman) Ltd sold $158.9K2026-02-23 · De Backer Marianne sold $141.8K2026-02-24 · De Backer Marianne sold $140.7K2026-02-25 · de Verneuil Vanina sold $134.5K2025-12-01 · SATO VICKI L sold $132.0K2026-01-02 · SATO VICKI L sold $130.5K2025-11-03 · SATO VICKI L sold $124.1K2026-03-23 · Sabatini Brent sold $70.3K2025-11-17 · O'Byrne Jason sold $37.8K2026-02-23 · de Verneuil Vanina sold $33.1K2026-06-01 · Napolitano Janet sold $30.2K2026-02-24 · de Verneuil Vanina sold $29.7K2026-02-25 · Eisner Mark sold $18.5K2026-02-24 · O'Byrne Jason sold $15.6K2026-02-23 · O'Byrne Jason sold $15.6K2026-02-23 · Eisner Mark sold $15.6K2026-02-24 · Eisner Mark sold $15.4K2026-02-24 · Sabatini Brent sold $13.6K2026-02-23 · Sabatini Brent sold $13.6K2025-11-05 · de Verneuil Vanina sold $12.3K2026-02-13 · Sabatini Brent sold $11.9K2025-11-03 · de Verneuil Vanina sold $8.0K2026-06-01 · Sabatini Brent sold $3.6K2026-02-24 · SATO VICKI L sold $2.1K2026-03-02 · SATO VICKI L sold $2.0K2025-10-29 · SVF Endurance (Cayman) Ltd sold $6492026-09-17 · O'Byrne Jason filed to sell $212.9K2026-09-09 · O'Byrne Jason filed to sell $315.2K2026-08-25 · O'Byrne Jason filed to sell $242.6K2026-08-24 · O'Byrne Jason filed to sell $142.1K2026-08-21 · O'Byrne Jason filed to sell $245.3K2026-06-29 · Ramasastry Saira filed to sell $165.1K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns VIR: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
20,678,283 sh
$210.7M
ARCH Venture Management, LLC
12,694,163 sh
$129.4M
VANGUARD PORTFOLIO MANAGEMENT LLC
11,495,215 sh
$117.1M
SB INVESTMENT ADVISERS (UK) LTD
10,948,093 sh
$111.6M
STATE STREET CORP
9,964,151 sh
$101.5M

Congress trades in VIR

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

VIR planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
O'Byrne Jason
Filed 2026-09-17
$212.9K
O'Byrne Jason
Filed 2026-09-09
$315.2K
O'Byrne Jason
Filed 2026-08-25
$242.6K
O'Byrne Jason
Filed 2026-08-24
$142.1K
O'Byrne Jason
Filed 2026-08-21
$245.3K

VIR mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares Genomics Immunology and Healthcare ETF
$2.5M position · as of 2026-07-31
1.3%
Global X Genomics & Biotechnology ETF
$619.1K position · as of 2026-05-31
1.1%
Nomura Healthcare Fund
$5.1M position · as of 2026-06-30
0.7%
Virtus Biotech Clinical Trials Etf
$312.6K position · as of 2026-07-31
0.7%
VANGUARD MARKET NEUTRAL FUND
$3.5M position · as of 2026-06-30
0.6%
Invesco S&P SmallCap Health Care ETF
$754.3K position · as of 2026-05-31
0.6%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
18 registered trials, 6 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
7
Phase 1
1 active
6
Phase 2
2 active
3
Phase 3
2 active
2
Multi-phase
1 active
What changed recently
Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434
2026-09-10 · Recruiting → Completed
Phase 1
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return · Dr. Scangos
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$7.8M
$3.1M
$2.0M
-77%
+25%
2024
$9.3M
$4.0M
$1.9M
-73%
-7%
2022
$7.5M
$3.5M
$4.0M
-5%
-10%
2021
$20.7M
$15.0M
$5.7M
+56%
+0%
2020
$994.9K
$34.5M
$1.4M
+113%
+26%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $254.9K sold by insiders over 180 days, 125 funds added last quarter, $1.2M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

VIR financials

Revenue growth
-7.6%
XBRL, annual
Net margin
-638.9%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$303.2M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-83.0%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$203.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-26.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-20.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-25.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-10.4%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$68.6M$74.2M$86.2M$1.6B
Operating income-$479.3M-$587.2M-$684.3M$833.1M
Net income-$438.0M-$522.0M-$615.1M$515.8M
EPS (diluted)-3.16-3.83-4.593.83
Operating cash flow-$391.8M-$446.4M-$778.8M$1.7B
Cash$232.2M$222.9M$241.6M$848.6M
SEC XBRL, fiscal years, as known on 2026-10-28

VIR Stock Sonar score 5/7 axes

Find similar shapesCompare

VIR ranks highest on profitability (68th percentile) and institutional and government (59th), and lowest on insider conviction (24th), among Pharma & Biotech peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
68
Inputs
  • Return on equity-26.1% · 69 pct, sector of 545
  • Return on assets-20.9% · 66 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-25.4% · 70 pct, sector of 576
Growth
36
Inputs
  • Revenue growth, YoY-7.6% · 36 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
24
Inputs
  • Net Form 4 buying (codes P and S), 180d-$255K · 48 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
59
Inputs
  • Funds adding, latest quarter125 · 77 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$200K · 41 pct, sector of 133
Risk and compliance
32
Inputs
  • Short interest, % of float+11.5% · 35 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+14.7% · 30 pct, sector of 511
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

VIR filings, in plain words

Are Vir Biotechnology insiders buying or selling VIR?

In the 180 days to 2026-10-28, Vir Biotechnology insiders were net sellers, a net $254.9K across purchases and sales reported on Form 4, by 3 sellers.

Are there planned insider sales of VIR?

Yes. 5 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $1.2M of stock; the latest, by O'Byrne Jason, was filed 2026-09-17.

Read the full summary

In the 180 days to 2026-10-28, Vir Biotechnology insiders were net sellers of VIR, a net $254.9K across purchases and sales reported on Form 4 by 3 sellers. None of the 3 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 5 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $1.2M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies